Securities class action litigation has been filed on behalf of investors who purchased or otherwise acquired the common stock of Baxter International, Inc. (“Baxter”) (NYSE: BAX) between February 23, 2022 and July 30, 2025, inclusive (the “Class Period”).

If you purchased or acquired Baxter common stock during the Class Period, you may move the Court for appointment as lead plaintiff by no later than December 15, 2025.

A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation. Your share of any recovery in the actions will not be affected by your decision of whether to seek appointment as lead plaintiff. You may retain Lieff Cabraser, or other attorneys, as your counsel in the action.

Baxter investors who wish to learn more about the litigation and how to seek appointment as lead plaintiff should complete the form below, text or email investorinfo@lchb.com, or call Lieff Cabraser partner Sharon M. Lee at 1-800-541-7358.

Baxter, headquartered in Deerfield, Illinois, develops, manufactures, and markets medical products used in the healthcare industry. The Company recently launched the Novum LVP, a device that controls the delivery of intravenous (“IV”) fluids that carry medications, blood products, and nutrients to patients.

The action alleges that, throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (a) Novum LVPs had been hampered by systemic defects causing malfunctions such as underinfusion, overinfusion, and non-delivery of fluids, which subject patients to serious risk of injury or death; (b) Baxter was notified of those Novum LVP malfunctions and related injuries and deaths; (c) Baxter’s attempts to remedy those defects were inadequate and  Novum LVP’s design flaws continued to cause serious harm to patients; and (d) as a result of the foregoing, there was a significant risk that Novum LVP customers would be asked to discontinue using existing Novum LVPs and that Baxter would pause new sales of the devices.

On April 7, 2025, Missouri news outlet KMOV reported significant safety issues with Novum LVP, specifically regarding the device’s inaccurate infusion rates, based on information from a whistleblower.  The KMOV report prompted the hospital system to take all its Novum LVPs out of service. Baxter nevertheless continued to promote the launch of Novum LVP and claimed it was a safe product.

On April 24, 2025, Baxter sent Novum LVP customers a warning letter about the device’s potential underinfusion risks and disclosed there had been only one serious injury linked to this issue.

On July 14, 2025, Baxter sent Novum LVP customers a second warning letter about the device’s risk of both underinfusion and overinfusion. The letter also disclosed that Baxter had received 79 serious injury reports and two reports of patient deaths tied to the device’s safety issues. Baxter, however, did not instruct hospitals to remove their Novum LVPs from service but rather directed them on correction steps while continuing to use the devices.

On July 31, 2025, Baxter announced that it was “voluntarily and temporarily paus[ing] shipments and planned installations of the Novum LVP,” and that the Company was “unable to currently commit to an exact timing for resuming shipment[s] and installation[s] for Novum LVPs.” Baxter’s Chief Operating Officer explained that the sales halt was in response to issues “we saw through our quality listening systems, customer feedback, and honestly our infusion data.” Following this news, Baxter’s stock price fell $6.29 per share, or 22.42%, from its closing price of $28.05 on July 30, 2025, to close at $21.76 on July 31, 2025, on significantly elevated trading volume.

Read our Securities and Investment Fraud Practice Area brochure